Apellis Pharmaceuticals won FDA approval for an expanded indication of its complement pathway drug pegcetacoplan (Empaveli), making it the second approved treatment for complement 3 glomerulopathy (C3G) and the first for primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The decision follows positive Phase III data demonstrating reductions in proteinuria, stable kidney function, and clearance of C3c deposits. Apellis CEO Cedric Francois described the approval as transformational for patients with these rare and severe kidney diseases.